SBI Securities Co. Ltd. Buys New Position in ImmunityBio, Inc. (NASDAQ:IBRX)

SBI Securities Co. Ltd. purchased a new position in ImmunityBio, Inc. (NASDAQ:IBRX) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 22,677 shares of the company’s stock, valued at approximately $58,000.

A number of other large investors also recently modified their holdings of the business. GSA Capital Partners LLP increased its holdings in shares of ImmunityBio by 290.3% during the 3rd quarter. GSA Capital Partners LLP now owns 107,985 shares of the company’s stock worth $402,000 after purchasing an additional 80,318 shares during the period. Intech Investment Management LLC bought a new position in ImmunityBio during the third quarter valued at about $253,000. Charles Schwab Investment Management Inc. raised its holdings in ImmunityBio by 2.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company’s stock valued at $4,709,000 after acquiring an additional 29,665 shares in the last quarter. Advantage Alpha Capital Partners LP bought a new stake in shares of ImmunityBio in the 3rd quarter worth approximately $257,000. Finally, Quantbot Technologies LP acquired a new stake in shares of ImmunityBio during the 3rd quarter worth approximately $143,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on IBRX. D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a research report on Friday, February 28th. BTIG Research began coverage on shares of ImmunityBio in a report on Friday, January 10th. They set a “buy” rating and a $6.00 price objective for the company. Finally, HC Wainwright assumed coverage on shares of ImmunityBio in a research note on Thursday, March 6th. They issued a “buy” rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, ImmunityBio presently has an average rating of “Buy” and an average price target of $12.19.

ImmunityBio Stock Performance

Shares of NASDAQ IBRX opened at $2.91 on Tuesday. ImmunityBio, Inc. has a 52-week low of $2.28 and a 52-week high of $10.53. The business has a fifty day moving average of $3.06 and a two-hundred day moving average of $3.69. The stock has a market cap of $2.48 billion, a PE ratio of -3.16 and a beta of 0.82.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to analyst estimates of $8.74 million. Analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.